D-0720-2021 Class II Terminated

Recalled by Eli Lilly & Company — Indianapolis, IN

Recall Details

Product Type
Drugs
Report Date
August 18, 2021
Initiation Date
June 29, 2021
Termination Date
July 29, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
36,540 vials

Product Description

Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01

Reason for Recall

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

Distribution Pattern

OH, MS, IN

Code Information

Lot # 197